Your browser doesn't support javascript.
loading
Inhibition of METTL3 Results in a Cell-Intrinsic Interferon Response That Enhances Antitumor Immunity.
Guirguis, Andrew A; Ofir-Rosenfeld, Yaara; Knezevic, Kathy; Blackaby, Wesley; Hardick, David; Chan, Yih-Chih; Motazedian, Ali; Gillespie, Andrea; Vassiliadis, Dane; Lam, Enid Y N; Tran, Kevin; Andrews, Byron; Harbour, Michael E; Vasiliauskaite, Lina; Saunders, Claire J; Tsagkogeorga, Georgia; Azevedo, Aleksandra; Obacz, Joanna; Pilka, Ewa S; Carkill, Marie; MacPherson, Laura; Wainwright, Elanor N; Liddicoat, Brian; Blyth, Benjamin J; Albertella, Mark R; Rausch, Oliver; Dawson, Mark A.
Afiliação
  • Guirguis AA; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Ofir-Rosenfeld Y; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
  • Knezevic K; Department of Clinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
  • Blackaby W; Storm Therapeutics Ltd, Cambridge, United Kingdom.
  • Hardick D; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Chan YC; Storm Therapeutics Ltd, Cambridge, United Kingdom.
  • Motazedian A; Storm Therapeutics Ltd, Cambridge, United Kingdom.
  • Gillespie A; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Vassiliadis D; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
  • Lam EYN; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Tran K; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
  • Andrews B; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Harbour ME; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Vasiliauskaite L; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
  • Saunders CJ; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Tsagkogeorga G; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
  • Azevedo A; Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Obacz J; Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia.
  • Pilka ES; Storm Therapeutics Ltd, Cambridge, United Kingdom.
  • Carkill M; Storm Therapeutics Ltd, Cambridge, United Kingdom.
  • MacPherson L; Storm Therapeutics Ltd, Cambridge, United Kingdom.
  • Wainwright EN; Storm Therapeutics Ltd, Cambridge, United Kingdom.
  • Liddicoat B; Storm Therapeutics Ltd, Cambridge, United Kingdom.
  • Blyth BJ; Milner Therapeutics Institute, University of Cambridge, Cambridge, United Kingdom.
  • Albertella MR; Storm Therapeutics Ltd, Cambridge, United Kingdom.
  • Rausch O; Storm Therapeutics Ltd, Cambridge, United Kingdom.
  • Dawson MA; Evotec (UK) Ltd, Abingdon, United Kingdom.
Cancer Discov ; 13(10): 2228-2247, 2023 10 05.
Article em En | MEDLINE | ID: mdl-37548590
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interferons / Metiltransferases Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Cancer Discov Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interferons / Metiltransferases Tipo de estudo: Prognostic_studies Limite: Animals Idioma: En Revista: Cancer Discov Ano de publicação: 2023 Tipo de documento: Article